These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 25831758)

  • 21. [Renal toxicity of anti-VEGF (corrected) targeted therapies].
    Vigneau C; Rioux-Leclercq N
    Nephrol Ther; 2013 Jun; 9(3):174-9. PubMed ID: 23410950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
    Ferrara N; Hillan KJ; Novotny W
    Biochem Biophys Res Commun; 2005 Jul; 333(2):328-35. PubMed ID: 15961063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Re: development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
    Ziemssen F; Heiduschka P; Schraermeyer U;
    Retina; 2007 Oct; 27(8):1154-6; author reply 1156-8. PubMed ID: 18040264
    [No Abstract]   [Full Text] [Related]  

  • 24. Adverse events associated with antiangiogenic agents in combination with cytotoxic chemotherapy in metastatic colorectal cancer and their management.
    Cartwright TH
    Clin Colorectal Cancer; 2013 Jun; 12(2):86-94. PubMed ID: 23562587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Development of novel angiogenesis inhibitors targeting VEGF (vascular endothelial growth factor) for cancer chemotherapy].
    Kakeya H; Osada H
    Nihon Rinsho; 2004 Jul; 62(7):1264-70. PubMed ID: 15283142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Avastin and new treatments for AMD: where are we?
    Freeman WR; Falkenstein I
    Retina; 2006 Oct; 26(8):853-8. PubMed ID: 17031283
    [No Abstract]   [Full Text] [Related]  

  • 27. Cutaneous manifestations of anti-angiogenic therapy in oncology: Review with focus on VEGF inhibitors.
    Ishak RS; Aad SA; Kyei A; Farhat FS
    Crit Rev Oncol Hematol; 2014 May; 90(2):152-64. PubMed ID: 24355408
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Anti-angiogenic drugs].
    Sato Y
    Nihon Rinsho; 2010 Oct; 68(10):1825-9. PubMed ID: 20954324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
    Tandle A; Libutti SK
    Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perspectives on lymphangiogenesis and angiogenesis in cancer.
    Holopainen T; Bry M; Alitalo K; Saaristo A
    J Surg Oncol; 2011 May; 103(6):484-8. PubMed ID: 21480240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Anti-angiogenesis targeting drugs: a review].
    Jia K; Li J
    Ai Zheng; 2008 Apr; 27(4):442-6. PubMed ID: 18423135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted Therapies in Cancer - Fourth International Congress. Angiogenesis inhibition.
    Tawbi H; Agarwala SS
    IDrugs; 2005 Dec; 8(12):984-6. PubMed ID: 16320129
    [No Abstract]   [Full Text] [Related]  

  • 33. Anti-angiogenic therapy in the treatment of advanced renal cell cancer.
    Board RE; Thistlethwaite FC; Hawkins RE
    Cancer Treat Rev; 2007 Feb; 33(1):1-8. PubMed ID: 17071006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular diagnosis of tumor angiogenesis and anti-angiogenic cancer therapy.
    Sato Y
    Int J Clin Oncol; 2003 Aug; 8(4):200-6. PubMed ID: 12955574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors.
    Kruzliak P; Novák J; Novák M
    Am J Hypertens; 2014 Jan; 27(1):3-13. PubMed ID: 24168915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The interaction of radiation therapy and antiangiogenic therapy.
    O'Reilly MS
    Cancer J; 2008; 14(4):207-13. PubMed ID: 18677126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
    Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
    Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiangiogenic therapy and surgical practice.
    John AR; Bramhall SR; Eggo MC
    Br J Surg; 2008 Mar; 95(3):281-93. PubMed ID: 18278790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Anti-EGFR antibodies].
    Takahashi M
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():219-23. PubMed ID: 25831756
    [No Abstract]   [Full Text] [Related]  

  • 40. Ocular Inflammation with Anti-Vascular Endothelial Growth Factor Treatments.
    Cheng SY; Punzo C
    Hum Gene Ther; 2021 Jul; 32(13-14):639-641. PubMed ID: 34283642
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.